Primary tumor location is an important predictive factor for wild‐type KRAS metastatic colon cancer treated with cetuximab as front‐line bio‐therapy

摘要: Introduction Left- and right-sided colon cancers were significantly different in epidemiologic, clinical histological parameters. However, the impact of primary tumor location metastatic cancer treated with front-line targeted triplet regimens is unclear, particularly Asian populations. Methods A total 121 patients KRAS exon 2 codon 12/13 wild-type enrolled between January 2007 December 2013. All received one target agent, such as cetuximab or bevacizumab, a regimen. The for bevacizumab groups was analyzed, respectively. Results In group, left-sided superior to objective response rate (70.1% vs 33.3%, P = 0.024), progression-free survival (15.0 5.3 months, P < 0.001) overall (35.8 14.4 months, P = 0.031). Primary an independent prognostic factor (hazard ratio 0.240, 95% confidence interval 0.114–0.508, P < 0.001). there no differences outcomes either side. insignificant univariate analysis. Conclusion Left-sided tumors favored cetuximab-based regimen cancer.